JPRN-jRCT2031210364进行中（未招募）1 期
ONO-4578-06: Phace I , Open-label, non-blind, first-line endocrine therapy with ONO-4578 and standard treatment letrozole and CDK4 /6 inhibitors (palbociclib or abemaciclib) in patients with metastatic or recurrent postmenopausal hormone receptor-positive HER2-negative breast cancer
Osawa Masahiro0 个研究点目标入组 40 人开始时间: 2021年10月2日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •1. Patients with postmenopausal metastatic or recurrent breast cancer
- •2. Patients with ECOG Performance Status 0 to 1
- •3. ER-positive, PgR-positive and HER2-negative patients
排除标准
- •1.Patients are unable to swallow oral medications
- •2.Patients with severe complication
研究者
相似试验
招募中
1 期
ONO-4578-02:ONO-4578 Phase 1 Studynresectable colorectal cancerJPRN-jRCT2031200215Hirashima Yoshinori36
招募中
1 期
ONO-7914-01:Phase I study of ONO-7914 alone and in combination with ONO-4538 in patients with solid tumorsJPRN-jRCT2031210530Hirashima Yoshinori204
进行中（未招募）
1 期
ONO-7119-01:Phase I study of ONO-7119 alone and in combination with ONO-4538 in patients with solid tumorsJPRN-jRCT2031210373Hirashima Yoshinori74
进行中（未招募）
1 期
ONO-7475-03 : ONO-7475 Phase 1 StudyEGFR mutated, stage IIIB/IIIC/IV or recurrent, NSCLC, which is unsuitable for radical irradiationJPRN-jRCT2051210045Osawa Masahiro75
招募中
1 期
ONO-4685-05:A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SRelapsed or refractory T-cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphomaJPRN-jRCT2011230051Osawa Masahiro108